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normalized absorbed doses (%) MOSFET film 
mean 95.0 96.4 
standard dev. 5.4 5.0 
u (MSE) 1.4 1.3 
2u (2 MSE) 2.8 2.6 
Table 1. Descriptive statistics of the in vivo data 
 
 Fig. 1. 
The uncertainty given for a single measurement based solely on 
detector and linac factors is greater and leads to a more conservative 
AL, whereas the AL derived from the MSE accounts for the variability 
involved in the whole procedure. 
Conclusions: An AL could be established after a thorough evaluation 
of the uncertainties associated with the in vivo dosimetry method 
employed. When added to the intended absorbed doses interval, this 
leads to non-action intervals (e.g. 85%-105% or 87%-103%, from our 
data and examples). As seen, these AL would remain coherent with in 
vivo dosimetry breast results already published and could be an initial 
proposal for future intervention protocols. 
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Purpose/Objective: Breast conserving therapy with complementary 
radiotherapy is an effective alternative for mastectomy; randomized 
trials in 20-years observations confirmed the comparable survivals in 
women treated with BCT and mastectomy. Standard procedure after 
BCT is whole breast irradiation (which reduces local risk of recurrence 
in about 16-30%) with higher dose on tumour bed (it decreases the risk 
of recurrence by 6%) for 5-7 weeks. The dose escalation may be 
proceeded by interstitial and cavital brachytherapy, intraoperative 
radiotherapy and conformal RT (3D-CRT) from external beams.  
In this study IORT was the only method used to boost the tumour bed. 
The aim of the study was to evaluate effectiveness of treatment, 
analyse early and late radiation reactions, cosmetic effect and quality 
of patients life.  
Materials and Methods: There were analysed 150 patients after BCT, 
IORT (10Gy/1 fraction; electron beam) and EBRT (50Gy/25 fractions; 
two tangential photon beams) with minimal observation period of 1 
year. The clinical profile is presented in table below. 
 
Tab.1  
Tumour size Number of 
pts. 
Tis 9 
T1mi 1 
T1a 1 
T1b 45 
T1c 79 
T2 15 
T3 0 
T4 0 
Histopatology Number of pts.
ductal invasive 71 
lobular invasive 2 
ductal invasive+DCIS 52 
lobular invasive+LCIS 1 
DCIS 8 
LCIS 0 
mucinous, apocrinal, tubular 16 
Patients number with feature N+: 25. 
 
During observation after IORTand in 1st, 6th, 12th, 24th and 36th 
month after EBRT we made: 
l physical examination,  
l photos of the breast,  
l analysis of acute and late toxicity.  
Patients filled in the quality of live questionnaires (QLQ-C30 and QLQ-
BR23) with the same frequency as observation schedule. 
Six months after EBRT mammography with ultrasounds of the breast 
was made in all patients.  
Results: No local recurrence occurred during observation period. 
Acute skin reactions in grade 1 and 2 were observed in 21,2% of 
patients, although therewere no acute and late toxicities both in 
grade 3 and 4. The cosmetic outcome according to the physical 
examination and photos analysis was good to excellent in 81,5% of 
patients. Pain in breast was observed in 20,6 % patients and 
hyperesthesia of the skin in 17,0 % patients. 
The edema of breast was reported by 81,3 % of patients after 1 
month, 63,4% after 6 months, 54,9 % after 1 year and 56% after 2 
years fromend of RT. The colour of breast skin has changed in 67,8 % 
of patients after 1 month, 44,1 % after 6 months, 37,8 % after 1 year, 
31% after 2 years from the end of RT. 
Conclusions: There was no local recurrences. IORT with EBRT was 
well tolerated, with no severe acute and late toxicities of the skin. 
The external beam course afterwards was shortenedby 1 week. After 
tumor resection the tumor bed can be precisely covered by the 
homogenous electron beam with no geographical mistake.  
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Purpose/Objective: Two randomized trials (Eliot; Targit) are showing 
encouraging data in favour of breast IORT in the field of partial breast 
irradiation. We present a new breast applicator to optimize the dose 
delivery with IORT using 50 kV X ray brachytherapy (XRB). 
Materials and Methods: In order to mimic the mamosite ® and 
intrabeam® applicator we developed an applicator to achieve the 
following characteristics: homogeneous dose at the surface of a 
spheric volume; protection of the skin overlying the surgical incision; 
good fixation and coaptation of the breast tissues of the tumor bed to 
the applicator; possible shielding of some tissues at risk (chest wall, 
lung); short treatment time and easy radioprotection. Between 2010 
and 2012 a series of dummy spherical applicators were tested with 
two breast surgeons to create the optimal sizes, shapes, fixation and 
shielding devices. A series of hollow nylon made applicators were then 
produced using a rapid prototyping procedure. These applicators were 
tested in sham irradiation with patients using the Papillon system 
(Ariane Medical systems™) delivering 50 kVp X-Rays. The dose 
distribution was measured and calculated with ion chamber, 
gafchromic films and a dedicated TPS with Monte Carlo algorythm 
(MC2Plan®). An international patent was given to the NBA. 
Results: Applicators between 3 and 6 cm diameter were tested 
(figure). The dose uniformity was excellent (± 4%) at the surface of 
the 310 ° spherical NBA (the isotropic X Ray source being in the center 
of the NBA). The percentage depth dose was in average (depending on 
the diameter of the NBA) 60% (of the surface dose) at 5 mm and 40% 
at 1cm. The eyelet positioned on the rim of the NBA made the fixation 
stable and the rim with the 310° beam resulted in a good protection 
of the overlying skin on the 'north pole' of the NBA. Thanks to forced 
cooling of the X ray tube anode, the Papillon system ® can deliver a 
typical 20 Gy treatment in 2 to 3 minutes. A flexible lead apron 
positioned at the surface of the patient during treatment made the 
radioprotection simple (medical and paramedical staff can stay in the 
OR during irradiation behind screen if needed). The first clinical 
results will be presented at the time of the meeting. 
Conclusions: The NBA used with the Papillon system provides a good 
dose distribution into the breast tumor bed after local excision. The 
easy and accurate positioning by the surgeon, the very short 
